Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRT1419 in Advanced Solid Tumors
NCT04837677Phase 1Completed
- Sponsor
- Prelude Therapeutics
- Start
- Aug 2021
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of PRT1419 in solid tumor, sarcoma, melanoma and 6 more, sponsored by Prelude Therapeutics. Primary endpoints: Dose Limiting Toxicities at Day 28, Maximally Tolerated Dose / Optimal Biological Dose at 2 years and 1 more. Started Aug 2021; status: completed.
02
Drugs
PRT1419
03
Conditions
solid tumorsarcomamelanomasmall cell lung cancer (SCLC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04837677.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04837677.